ONO-4685
Sponsors
Ono Pharmaceutical Co. Ltd, Ono Pharmaceutical Co., Ltd.
Conditions
Healthy VolunteersPlaque PsoriasisRelapsed or Refractory T Cell LymphomaRelapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects
CompletedNCT04079062
Start: 2019-09-12End: 2021-05-25Updated: 2024-05-03
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Active, not recruitingNCT05079282
Start: 2021-12-10End: 2028-08-31Target: 217Updated: 2026-09-29
Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
CompletedNCT05332704
Start: 2022-03-25End: 2024-07-18Updated: 2024-08-21
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Active, not recruitingNCT06547528
Start: 2023-10-01End: 2029-04-30Target: 108Updated: 2026-09-28